- Home
- ZYXI
ZYXI
Zynex Inc.
as 07-26-2024 4:00pm EST
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | ENGLEWOOD |
| Market Cap: | 320.9M | IPO Year: | N/A |
| Target Price: | $15.50 | AVG Volume (30 days): | 167.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.18 | EPS Growth: | -60.87 |
| 52 Week Low/High: | $6.88 - $13.77 | Next Earning Date: | 07-25-2024 |
| Revenue: | $193,614,000 | Revenue Growth: | 9.11% |
| Revenue Growth (this year): | 25.59% | Revenue Growth (next year): | 23.75% |
Latest Zynex Inc. News
ZYXI Breaking Stock News: Dive into ZYXI Ticker-Specific Updates for Smart Investing
Motley Fool
4 hours ago
Why Zynex Plunged Today
Thomson Reuters StreetEvents
8 hours ago
Q2 2024 Zynex Inc Earnings Call
MT Newswires
13 hours ago
Top Premarket Decliners
Zacks
a day ago
Zynex Inc. (ZYXI) Q2 Earnings and Revenues Lag Estimates
PR Newswire
a day ago
Zynex Reports Second Quarter 2024 Financial Results
PR Newswire
9 days ago
Zynex Sets Second Quarter 2024 Earnings Call
Simply Wall St.
15 days ago
Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 36%?
PR Newswire
15 days ago
Zynex Recognized as a Best Company to Work For by U.S. News & World Report and Top Workplaces
Compare ZYXI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZYXI Zynex Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.